Radiolabeling and biological evaluation of 125 I-Necitumumab for EGFR-targeted SPECT imaging
In this study, the SPECT probe125I-Necitumumab were synthesized and evaluated for SPECT imaging of non-small cell lung cancer (NSCLC). In vivo biodistribution study indicated that125I-Necitumumab was cleared rapidly in most organs and tissues. Though the tumor expressed a relatively high level of EGFR, however SPECT images showed no obvious uptake in the tumors. Therefore, we considered that125I-Necitumumab was not suitable for EGFR-targeted NSCLC SPECT imaging.
AbstractWhile molecular imaging with positron emission tomography or single-photon emission computed tomography already reports on tumour molecular mechanisms on a macroscopic scale, there is increasing evidence that there are multiple additional features within medical images that can further improve tumour characterization, treatment prediction and prognostication. Early reports have already revealed the power of radiomics to personalize and improve patient management and outcomes. What remains unclear is how these additional metrics relate to underlying molecular mechanisms of disease. Furthermore, the ability to deal w...
ConclusionThe incorporation of functional imaging for radiotherapy planning in non-small cell lung cancer is feasible and appears to be beneficial in preserving a functional lung in non-small cell lung cancer.
Conclusion: This first-in-human study demonstrates that 99mTc-labeled anti–PD-L1-single-domain antibody SPECT/CT imaging is safe and associated with acceptable dosimetry. Tumor uptake is readily visible against background tissues, particularly at 2 h when the T:BP ratio correlates with PD-L1 immunohistochemistry results.
CONCLUSION: A 10-20 Gy radiation dose to anatomic or perfused lung results in decline in FEV1. A fractional anatomic volume of>5% receiving>50 Gy influences development of RALI. ADVANCES IN KNOWLEDGE: Extent of low-dose radiation to normal lung influences functional respiratory decline. PMID: 31287737 [PubMed - as supplied by publisher]
Conclusions: This first in human study demonstrates that 99mTc-labeled anti-PD-L1-sdAb SPECT/CT imaging is safe and associated with acceptable dosimetry. Tumor uptake is readily visible against background tissues, particularly at 2h when the T:BP ratio correlates with IHC PD-L1 expression.
Conclusions: 123I-labeled L- and D-iodohistidine were synthesized by a simple iodogen method with a high radiochemical purity. In vitro experiments demonstrated high L-[123I]iodohistidine uptake by NSCLC cells, but in vivo studies confirmed that D-[123I]iodohistidine is a superior tumor imaging agent for SPECT/CT. Acknowledgements: This research was partially supported by NRF-2017M2A2A7A01071134, NRF-2015M2C2A1047687, and HI15C3093.
In this study, we investigated the association between 99mTc-3PRGD2 SPECT/CT imaging and tumor angiogenesis by analyzing images and postoperative pathological findings in patients with non-small cell lung cancer(NSCLC). Methods: Retrospectively collected data from 56 patients who underwent 99mTc-3PRGD2 SPECT/CT imaging in our department from July 2015 to December 2016 and were able to obtain postoperative pathological block within seven days. Calculate the ratio of the highest uptake value of the lesion (T) to the contralateral normal lung (N) uptake value, and determine the T/N ratio of 99mTc-3PRGD2 SPECT/CT imaging for t...
Elevated expression of the c-Met receptor plays a crucial role in cancers. In non–small cell lung cancer (NSCLC), aberrant activation of the c-Met signaling pathway contributes to tumorigenesis and cancer progression and may mediate acquired resistance to epidermal growth factor receptor–targeted therapy. c-Met is therefore emerging as a promising therapeutic target for NSCLC, and methods for noninvasive in vivo assessment of c-Met expression would improve NSCLC treatment and diagnosis. Methods: We developed a new c-Met–binding peptide (cMBP) radiotracer, 99mTc-hydrazine nicotinamide (HYNIC)-cMBP, for SPE...
ConclusionMicro ‐SPECT/CT imaging through99mTc ‐tricine‐EDDA‐Hynic‐c‐Met can be used to screen c‐Met indicators of NSCLC in H1993 nude mice models for targeted drug therapy.This article is protected by copyright. All rights reserved.
Conclusions: Using c-Met as the target, SPECT/CT imaging through radioactive isotopes labeled 99Tcm-tricine-EDDA-Hynic-c-Met molecular probe can be used to screen indicators of NSCLC treated by c-Met inhibitor-mediated targeted drug therapy, which provides idea for further research.